Frank o. by Frank O.
Bloomberg | Getty image
Swiss Pharmaceutical Giant Nuohua The sales in the fourth quarter exceeded expectations in the fourth quarter, but there was no own guidance throughout the year.
The net sales in the fourth quarter increased by 16 % based on constant currencies to $ 13.2 billion, while analysts estimated $ 12.795 billion in LSEG Public Opinion Survey.
The quarterly adjusted core operating income was US $ 4.86 billion, compared with US $ 4.23 billion.
In 2024, net sales rose 12 % based on constant currencies to US $ 50.32 billion, while prediction was $ 50.47 billion. Compared with the predicted $ 1702 billion, core operating income of the year has increased by 22 % to $ 19.5 billion.
In October, Novartis increased its revenue guide for 2024 in October, saying that it is expected to increase the “high adolescent” percentage of net sales and core operating income of the year, rather than the previously predicted “middle and high grades.”
CEO VAS Narasimhan said that since the strategic repair of the business in 2023, the results marked positive early signals.
Narasimhan said in a statement: “In the first year as a pure innovation pharmaceutical company, Novartis provided one of our strongest financial performance in history. CC.
He said: “With the momentum we see in our business, we expect to expand sales growth in 2025 and maintain a good attitude to achieve our midterm guidance.”
Looking forward to the future, Narasimhan said that the company focuses on promoting its development channels, including more than 30 kinds of assets “may promote differentiated growth in the long run.”
The company also outlines its guidance in 2025. It is predicted that net sales will increase “median to unit numbers”, and core operating income will increase “high unit to low two digits.”
This is a shocking news story that will be updated soon.
